The regulatory status of NAD+ and its precursors has changed several times in recent years and continues to evolve. This article reflects the most up-to-date verified information available at the time of its preparation. As the situation in this area can change rapidly, the legal status is best considered on a country- or region-specific basis and always with reference to a specific point in time, particularly when purchasing, prescribing, importing, or selling NAD+-related products.
Is it legal to buy and use NAD+?
NAD+ and its most commonly used precursors are not classified as controlled substances in the United States, the European Union or the United Kingdom, which is why merely possessing them is generally legal.
However, legal possession and legal sale are separate regulatory issues. Whether a given product can be legally placed on the market depends on the specific compound, formulation, intended use, and jurisdiction.
Oral nicotinamide riboside, or NR, currently has the most transparent regulatory status among the major NAD+ precursors.
In the United States, NR, sold as Niagen by Niagen Bioscience, formerly ChromaDex, holds a self-affirmed Generally Recognized as Safe status and has received positive New Dietary Ingredient notifications from the FDA. This allows qualifying products containing NR to be marketed as dietary supplements in accordance with applicable US requirements [1].
In the European Union, in 2019, NR received a positive safety opinion from the European Food Safety Authority. Subsequently, it obtained authorisation as a Novel Food, which allows the sale of products containing NR in EU member states, provided they meet the approved conditions and specifications [2].
Oral NMN has had a significantly less stable regulatory history, particularly in the United States. Its status has changed notably over the last few years and is discussed separately below.
Niacin and nicotinamide, which are standard forms of vitamin B3, have a significantly longer and better-established regulatory history. Both substances are widely used as food supplements and food fortificants in the USA, the EU and the UK.
Injectable and intravenous NAD+ fall into a different regulatory category. These products are not regulated like standard consumer dietary supplements and in the United States are typically supplied as compounding pharmacy preparations.
Does NAD+ require a prescription?
Prescription requirements depend primarily on the product's form and its regulatory category.
Oral NAD+ precursor supplements, including NR and currently NMN in the United States, generally do not require a prescription provided they are legally marketed as dietary supplements and comply with applicable regulatory requirements.
The situation is different in the case of injectable and intravenous NAD+.
NAD+ has not been approved by the FDA as a drug for any indication, and there is no FDA-approved injectable NAD+ product sold as a standard prescription or over-the-counter medicine.
The injectable and intravenous NAD+ products available in some clinics, telehealth services and pharmacies are typically compounded preparations rather than FDA-approved standardised drugs [3].
In the United States, these products may be prepared by state-licensed 503A pharmacies or by 503B outsourcing facilities.
503A pharmacies typically compound medication for a specific patient based on a valid prescription. By contrast, a 503B facility can manufacture larger batches of products under a different regulatory framework and with additional federal oversight.
Because compounding injectable medicines are supplied as part of the medical and prescription system, access to injectable or intravenous NAD+ in the United States typically requires a prescription or order from a licensed healthcare professional.
This regulatory status should not be confused with FDA approval. A compounding NAD+ product can be legally prepared and prescribed in accordance with applicable pharmacy compounding rules without having FDA-approved drug status.
What is the FDA's current position on compounded NAD+ injections?
The regulatory status of compounded NAD+ injections has developed significantly in recent years.
Plain NAD+ has never been approved by the FDA as a drug for any indication and there is currently no FDA-approved injectable NAD+ product available. Injectable and intravenous NAD+ products supplied by clinics or compounding pharmacies are therefore compounded preparations rather than approved drugs [3].
The FDA has also taken specific enforcement and safety actions regarding prescription NAD+ products.
In 2024, the agency reminded compounding pharmacies that NAD+ used in sterile injectable preparations must be of pharmaceutical grade and from an appropriate source. Food-grade or research-grade NAD+ was not considered appropriate for use in sterile compounded injectable preparations [4].
A more serious safety event occurred in October 2025, when the FDA identified a Class I recall of a prescription NAD+ injection product due to bacterial endotoxin contamination [4].
A Class I recall is the most serious FDA recall category and is used when exposure to a product carries a reasonable probability of causing serious health consequences or death.
Following the product recall in January 2026, the FDA issued a warning letter to the manufacturer, pointing out violations of federal drug manufacturing requirements applicable to outsourcing facilities [4].
These actions concern the quality and method of manufacturing compounded NAD+ products for injection, rather than a statement that NAD+ itself is categorically prohibited.
NMN has undergone a separate and particularly complex regulatory path.
In November 2022, the FDA determined that NMN is excluded from the legal definition of a dietary supplement under federal provisions concerning ingredients previously authorised for investigation as new drugs [5].
The agency based this decision on the Investigational New Drug application for the NMN-related drug candidate MIB-626, considering that it was authorised for clinical trials before NMN was legally marketed as a dietary supplement.
This decision caused significant disruption in the American supplement market, including the removal of NMN products from several major sales platforms.
Following legal challenges and industry petitions, the FDA changed its position in September 2025 and recognised that NMN is not excluded from the definition of a dietary supplement [5].
The agency subsequently confirmed this position directly to ingredient suppliers in December 2025.
According to the current regulatory position described here, NMN may once again be legally marketed in the United States as a dietary supplement, provided that other applicable supplement requirements are met.
The rapid shift from exclusion in 2022 to a U-turn in 2025 shows how quickly the regulatory status of NAD+-related compounds can change.
Is NAD+ banned in sport or certain professional environments according to WADA?
NAD+ itself does not appear by name on the World Anti-Doping Agency's current Prohibited List [6].
However, intravenous administration introduces a separate anti-doping issue.
In accordance with WADA category M2.2 relating to chemical and physical manipulation, intravenous infusions or injections exceeding a total volume of 100 ml per 12-hour period are prohibited regardless of the substance administered [7].
Exceptions include situations where the infusion is legally used during hospital treatment, a surgical procedure or a clinical diagnostic study.
This means that the anti-doping issue may relate to the method of administration rather than the NAD+ itself.
NAD+ infusion session IV involving more than 100 ml per 12 hours may therefore be subject to the prohibition regarding the method of administration for an athlete subject to WADA regulations, even though NAD+ itself is not separately listed as a prohibited substance.
Similar restrictions on the volume of IV infusions have led to sanctions in other sporting contexts when athletes have received standard intravenous fluids without realising that the method of administration itself is restricted [7].
Oral NR, NMN, niacin and nicotinamide are not subject to this specific intravenous infusion volume restriction, as they are not administered via IV infusion.
Anti-doping status remains subject to current regulations, as the WADA Prohibited List is updated annually. Anti-doping organisations for individual sports may also publish additional interpretations or requirements.
How do regulations in the UK and EU compare to those in the United States?
Regulatory requirements vary significantly between the United States, the European Union and the United Kingdom.
FDA regulations apply exclusively to the US market and do not determine whether a given product can be legally sold in the EU or the UK. Each jurisdiction operates on the basis of its own laws, authorisation procedures and enforcement systems.
In the European Union, novel foods are subject to the Novel Food Regulation (EU) 2015/2283.
An ingredient without a significant history of consumption as food in the EU before May 1997 generally requires a special authorisation before it can be legally placed on the market as a food or food supplement.
NR underwent this process after obtaining a positive EFSA safety evaluation in 2019. It subsequently received authorisation as a Novel Food, enabling the sale of compliant NR products in EU member states within the approved specifications [2].
NMN is in a different situation.
EFSA issued a positive safety opinion on NMN in May 2026, stating that an intake of up to 300 mg per day is safe for adults, excluding pregnant and breastfeeding women [8].
However, a positive EFSA opinion is not in itself final authorisation for placing the product on the market.
The formal Novel Food authorisation still requires the completion of the procedure conducted by the European Commission, along with the relevant stages involving EU member states.
Until this process is completed, NMN does not have the same finalised Novel Food authorisation status in the EU as NR.
In practice, NMN products continue to appear on the European market, and this situation is frequently described in industry publications as a regulatory grey area while awaiting final authorisation.
Post-Brexit Britain operates under a separate system.
Great Britain, comprising England, Scotland and Wales, operates its own Novel Food authorisation process administered by the Food Standards Agency.
Although the British and EU systems are based on similar principles, authorisation in one jurisdiction does not mean automatic authorisation in the other.
As per the regulatory status described here, NMN has not received final Novel Food authorisation in the UK [9].
Products nevertheless remain widely available on the market, creating a discrepancy between the formal authorisation status and actual commercial availability.
Therefore, the overall regulatory landscape is heavily dependent on the jurisdiction.
NR has a relatively well-established status in the United States and the European Union.
Following a change in the FDA's stance in 2025, NMN currently once again has the status enabling it to be legally marketed as a dietary supplement in the United States, whereas its formal Novel Food status remains less definitively resolved in the EU and the UK.
Injectable and intravenous NAD+ are subject to separate medical and compounding frameworks and should not be treated as equivalent to orally sold supplements.
Limitations of this information
- The regulatory status of NAD+ and its precursors, particularly NMN, has changed several times in a short period and may still change further.
- The information summarised here reflects the most up-to-date verified status available at the time of the article's preparation, rather than a permanent legal classification.
- Legal status may vary depending on the compound, formulation, route of administration, intended use, labelling, method of production and jurisdiction.
- The article summarises regulatory information and enforcement actions originating from government agency announcements and contemporary industry or news publications, rather than from peer-reviewed clinical studies, which is appropriate for a question concerning legal and regulatory status.
- The FDA's position relates to the United States and does not determine the regulatory status in the European Union or the UK.
- A positive scientific opinion from EFSA does not automatically mean final European Commission Novel Food authorisation.
- Commercial availability does not necessarily mean that the product has undergone all required regulatory procedures.
- Lawful preparation of a compounded injectable product does not mean that the product has obtained FDA approval as a drug.
- The WADA Prohibited List of Substances and Methods and related guidelines are regularly updated, so anti-doping classification and restrictions regarding the route of administration may change over time.
- Enforcement of regulations on food supplements and Novel Food can vary in practice between individual EU member states, UK authorities, and US states, even where broader federal or regional frameworks apply.
Disclaimer
The article is for general educational purposes only and provides a summary of regulatory information. It does not constitute legal, regulatory, medical, prescription, import, or business advice.
The legal status of NAD+, NR, NMN and related products varies depending on the jurisdiction, formulation, route of administration, intended use, labelling and current decisions of regulatory authorities.
Regulatory classifications can change, especially in the case of newer ingredients such as NMN. When legal or regulatory status is important for a specific decision, the primary source should be current official information from the FDA, EFSA, European Commission, FSA, MHRA, WADA or other competent authorities.
NAD+ and its precursors should not be presented as FDA, EMA or equivalent regulatory authority approved medicines for the treatment, prevention or cure of diseases, unless referring to a specific approved medicinal product and indication.
Commercial availability, legal possession, dietary supplement status, Novel Food authorisation, legal compounding in a pharmacy and formal approval as a medicinal product are distinct regulatory concepts and should not be treated as equivalent.
References
[1] Niagen Bioscience (formerly ChromaDex). (2016). Generally Recognized as Safe (GRAS) self-affirmation and New Dietary Ingredient notifications for nicotinamide riboside chloride (Niagen). U.S. Food and Drug Administration.
[2] European Food Safety Authority. (2019). Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal.
[3] U.S. Food and Drug Administration. (2024–2026). Compounding and the FDA: Questions and answers; 503A and 503B facility guidance. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding
[4] U.S. Food and Drug Administration. (2025–2026). Recalls, market withdrawals & safety alerts: Compounded NAD+ injectable products. U.S. Food and Drug Administration. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts
[5] U.S. Food and Drug Administration. (2022, November; 2025, September). Constituent update: Nicotinamide mononucleotide (NMN) dietary supplement determination. U.S. Food and Drug Administration. https://www.fda.gov/food/cfsan-constituent-updates
[6] World Anti-Doping Agency. (2026). The 2026 Prohibited List. World Anti-Doping Agency. https://www.wada-ama.org/en/prohibited-list
[7] U.S. Anti-Doping Agency. (2026). IV infusion: Explanatory note. U.S. Anti-Doping Agency. https://www.usada.org/athlete-advisory/iv-infusions-explanatory-note/
[8] European Food Safety Authority. (2026, May). Scientific opinion on the safety of synthetic beta-nicotinamide mononucleotide (β-NMN) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA Journal.
[9] UK Food Standards Agency. (2025–2026). Novel food applications and authorisations register. Food Standards Agency. https://www.food.gov.uk/business-guidance/novel-foods